Recovery Or Purification Patents (Class 435/239)
  • Patent number: 10329536
    Abstract: The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; in which culturing occurs in a volume of at least 30 L. The invention also concerns a method for production of a drug or diagnostic agent in which an active ingredient is produced according to the above method and mixed with an appropriate adjuvant, auxiliary, buffer, diluent or drug carrier.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 25, 2019
    Assignee: Seqirus UK Limited
    Inventors: Jürgen Vorlop, Christian Frech, Holger Lübben, Jens-Peter Gregersen
  • Patent number: 10294460
    Abstract: The disclosure provides methods for poliovirus purification from crude cell culture harvests using a detergent followed by a clarification step.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 21, 2019
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Mariken Segers, Beckley Kungah Nfor, Feras Nachmi Alazi, Marcel Leo De Vocht
  • Patent number: 10160956
    Abstract: The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography. The proposed method is useful in the display of selected polypeptided on a bacteriophage capsid without the need to genetically modify the bacteriophage, and thus makes it possible to produce phage preparations for various uses using wild-type phages occurring naturally or others not additionally modified for phage-display purposes.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 25, 2018
    Inventors: Krystyna Dabrowska, Anna Oslizlo, Paulina Budynek, Agnieszka Otrowicz, Andrzej Gorski, Grzegorz Figura, Barbara Owczarek, Agnieszka Kopciuch
  • Patent number: 10101262
    Abstract: A method for evaluating a biological material for unassociated virus-size particles having a particular epitope indicative of an adeno-associated virus viral type or an adenovirus viral type uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 16, 2018
    Assignee: IntelliCyt Corporation
    Inventors: Michael A. Artinger, Francis Kevin Kohlmeier, Michael W. Olszowy, Tyler Donald Gates
  • Patent number: 10087423
    Abstract: The present invention provides methods and systems for recovering an essentially cell-associated expression product from a host cell comprising (a) culturing said host cell under conditions that allow expression of said expression product; (b) collecting said host cell in/on a filter unit; (c) disrupting said host cell in/on the filter unit; and (d) separating said expression product from said disrupted host cell. The present invention also provides an expression product obtainable by the methods or systems, wherein the expression product is a poxvirus.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: October 2, 2018
    Assignee: BAVARIAN NORDIC A/S
    Inventors: Engelbert Wehnes, Uwe Werner, Christian Leschke
  • Patent number: 10076565
    Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: September 18, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Ruxandra Draghia-Akli, David B. Weiner, Jian Yan, Dominick Laddy
  • Patent number: 10072250
    Abstract: The present invention provides a method for efficiently manufacturing a non-enveloped virus with high purity without laborious operation by cultivating cells having the ability to produce a non-enveloped virus and bringing the cells and an acidic solution into contact with each other. A non-enveloped virus vector manufactured by the method of the present invention and a composition having the non-enveloped viral vector as an active ingredient are very useful as gene transfer methods in the fields of basic research and clinical application gene therapy.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: September 11, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Shuhei Sakamoto, Yasuhiro Kawano, Katsuyuki Dodo, Tatsuji Enoki, Hirofumi Yoshioka, Hikaru Takakura, Junichi Mineno
  • Patent number: 10041049
    Abstract: The invention provides methods for large-scale production of recombinant adenovirus 35, using perfusion systems and infection at very high-cell densities.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: August 7, 2018
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Alfred Luitjens, John A. Lewis
  • Patent number: 10036747
    Abstract: The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: July 31, 2018
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Zeev Pancer, Li Mao, Xia Hong, Mark Z. Ma
  • Patent number: 9809639
    Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: November 7, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Peter Stanley Gagnon
  • Patent number: 9610352
    Abstract: Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 4, 2017
    Assignee: Oncolytics Biotech Inc.
    Inventors: Matthew C. Coffey, Sarah Serl, Leo Pavliv
  • Patent number: 9574181
    Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 21, 2017
    Assignee: Seqirus UK Limited
    Inventors: Heidi Trusheim, Peter Mason, Michael Franti, Björn Keiner, Melissa Sackal, Juerg Hunziker, David Morrissey, François Jean-Charles Natt
  • Patent number: 9528126
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 9492840
    Abstract: A method for removing an organic ligand from a surface of a particle including: obtaining a particle having an organic ligand disposed on a surface thereof; contacting the particle with an alkylammonium salt represented by Chemical Formula 1: NR?4+A???Chemical Formula 1 wherein groups R? are the same or different and are each independently hydrogen or a C1 to C20 alkyl group, provided that at least one group R? is an alkyl group, and A is a hydroxide anion, a halide anion, a borohydride anion, a nitrate anion, a phosphate anion, or a sulfate anion; and heat-treating the particle to carry out a reaction between the alkylammonium salt and the organic ligand.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: November 15, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Yeon Lee, Jun Ho Lee, Kyungsang Cho, Young Suk Jung
  • Patent number: 9464281
    Abstract: A method for concentrating viruses includes applying a magnetic force to a mixture containing: sugar chain-immobilized magnetic metal nano-particles each having a structure in which a sugar chain-immobilized metal nano-particle is bound to a first magnetic nano-particle; second magnetic particles with mean particle size larger than that of the sugar chain-immobilized magnetic metal nano-particles; and a specimen. Each sugar chain-immobilized metal nano-particle has a structure where a ligand-conjugate is bound to a metal nano-particle via sulfur atoms. The ligand-conjugate has a structure where a linker compound's amino group is connected to a sugar chain having a reducing terminal. The linker compound includes, in molecules thereof, an amino group, sulfur atoms, and a hydrocarbon chain having carbon-nitrogen bonds.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: October 11, 2016
    Assignees: SUDx-Biotec Corporation, National University Corporation Kagoshima University, Neat Co., Ltd.
    Inventors: Yasuo Suda, Masahiro Wakao, Takashi Kodama
  • Patent number: 9295702
    Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 29, 2016
    Assignee: Transgene S.A.
    Inventors: Daniel Malarme, Yves Cordier, Claude Sene
  • Patent number: 9233912
    Abstract: The invention in some aspects relates to devices and methods for nucleating crystals under controlled conditions. In some aspects of the invention, devices and methods are provided for continuous crystallization.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 12, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Allan Stuart Myerson, Shin Yee Wong
  • Patent number: 9182395
    Abstract: This invention relates to an assay device and a method for pretreating a specimen containing a biologically-relevant substance and then assaying the biologically-relevant substance. Biologically-relevant substances used in the assay method include microorganisms, cells, viruses, nucleic acids, polysaccharides, proteins (including antigens, antibodies, chromoproteins, and enzymes), peptides, nucleic acids, and small molecules. This pretreatment method removes contaminants from the biologically-relevant substances using supports such as magnetic particles, gels, resins, membranes, and solid-phased reagents. Therefore, in the assay method the following steps are generally carried out (i) a pretreatment step of treating a specimen using one or more first supports and then one or more second supports, and (ii) the assay step carried out after the pretreatment step. In particular, the pretreatment method reduces false positives and false negatives in the assay.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: November 10, 2015
    Assignee: UNIVERSAL BIO RESEARCH CO., LTD.
    Inventor: Hideji Tajima
  • Patent number: 9175052
    Abstract: The disclosure describes methods for the purification of protein-enriched extracts to provide concentrates and isolates and methods for incorporation of such materials into products. The purification methods are adapted for removal of one or more of ash, metal salts, alkaloids, particulates, heavy metals, and other impurities and/or contaminants from extracts, as well as modifying the sensory characteristics (e.g., odor, color, and/or taste characteristics) of extracts. The methods generally include diafiltration, treatment with functionalized resins, and supercritical extraction. A protein composition in the form of a concentrate or isolate is provided, the protein composition including RuBisCO, F2 fraction proteins, or combination thereof extracted from a plant of the Nicotiana species, wherein the protein composition is characterized by one or more of: an ash content of less than about 15% by weight; a nicotine content of less than about 10 ?g/g; and a heavy metal content of less than about 60 ?g/g.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 3, 2015
    Assignee: R.J. Reynolds Tobacco Company
    Inventors: Anthony Richard Gerardi, Crystal Dawn Hege Byrd, Thaddeus Jude Jackson, Chelsea Allison Betts, John-Paul Mua, Kyle Ford
  • Patent number: 9173989
    Abstract: The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: November 3, 2015
    Assignee: EXTHERA MEDICAL CORPORATION
    Inventors: Olle Larm, Tomas Bergström
  • Patent number: 9169491
    Abstract: A process for producing a retroviral or lentiviral vector formulation comprising a filter-sterilization step wherein the filter-sterilization step is not the final step in the purification process.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: October 27, 2015
    Assignee: Oxford BioMedica (UK) Limited
    Inventors: Richard Truran, Robert Buckley, Pippa Radcliffe, James Miskin, Kyriacos Mitrophanous
  • Patent number: 9109201
    Abstract: The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: August 18, 2015
    Assignees: Bavarian Nordic A/S, Otto-von-Guericke-Universität, Sartorius Stedim Biotech GmbH
    Inventors: Sara Post Hansen, Rene Faber, Udo Reichl, Michael Wolff, Anders Peter Gram
  • Patent number: 9085753
    Abstract: The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: July 21, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Jonathan Liu, Mark Thompson, Luis J. Maranga, Floro Cataniag, Simon S. Hsu
  • Patent number: 9051542
    Abstract: Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. ?˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 9, 2015
    Assignee: Genzyme Corporation
    Inventors: John Fraser Wright, Guang Qu
  • Patent number: 9045777
    Abstract: The present invention relates to a pol I promoter derived from Vero cells and a recombinant vector containing the same. When the pol I promoter derived from Vero cells according to the present invention is utilized, viruses can be manufactured efficiently, and consequently, the manufacture of both seasonal influenza vaccine and pandemic vaccine can be prepared more quickly to usefully address either situation.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: June 2, 2015
    Assignees: Korea Center for Disease Control and Prevention, Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Young Ki Choi, Chun Kang, Kee Jong Hong, Min Suk Song, Yun Hee Baek
  • Patent number: 9028839
    Abstract: The invention relates to a vaccine composition comprising: a) inactivated whole virus, and b) a stabilizing excipient which comprises: i. a buffer solution, ii. a mixture of essential and nonessential amino acids, iii. a disaccharide, iv. a polyol, v. a chelating agent, vi. urea or a urea derivative, and vii. a nonionic surfactant.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: May 12, 2015
    Assignee: Sanofi Pasteur S.A.
    Inventors: Alain Francon, Michel Chevalier, Nadege Moreno, Eric Calvosa, Sandrine Cigarini, Virginie Fabre
  • Publication number: 20150125929
    Abstract: The present invention relates to novel and improved methods for the purification of biomolecules. In particular, the present invention relates to methods of protein purification which employ a porous solid support modified with a charged fluorocarbon composition.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Inventors: Mikhail Kozlov, Wilson Moya, Jad Jaber, William Cataldo, Ajish Potty, Christopher Gillespie
  • Patent number: 9023603
    Abstract: The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: May 5, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann
  • Patent number: 9012198
    Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: April 21, 2015
    Assignee: Transgene S.A.
    Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
  • Patent number: 9006420
    Abstract: A simple and convenient method for concentrating a biomolecule, including protein or nucleic acid molecules, from a sample. Purified and isolated biomolecules obtained by this method. Methods for improving the specificity or sensitivity of detecting a biomolecule by concentration and/or purification or isolation of the biomolecule according to the method of the invention.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: April 14, 2015
    Inventor: Timo Hillebrand
  • Publication number: 20150093804
    Abstract: A recombinant baculovirus is provided for preparing picornavirus virus-like particles (VLP), wherein Chitinase A (ChiA) and Cathepsin V (v-cath) genes of the recombinant baculovirus are functionally disrupted and the recombinant baculovirus includes a picornavirus capsid protein gene under control of a strong promoter, and includes a protease gene configured for encoding a protease for hydrolyzing the capsid protein under control of a weak promoter. The recombinant baculovirus of the present invention may adopt High Five or Sf-9 cells for manufacturing enterovirus virus-like particles with improved stability and higher yields in comparison with the conventional arts. A method for preparing virus like particles is also herein provided.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Inventors: YU-CHEN HU, SHIH-YEH LIN
  • Patent number: 8993229
    Abstract: A method for extracting and distinguishing infectious norovirus from inactive norovirus using a solid support conjugated with a glycoprotein moiety capable of binding infectious norovirus wherein the presence of infectious norovirus is determined using RT-PCR after elution of the infectious norovirus from the solid support.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventor: David H. Kingsley
  • Publication number: 20150064770
    Abstract: Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity.
    Type: Application
    Filed: September 5, 2014
    Publication date: March 5, 2015
    Applicant: Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Hiroki Ando, Sebastien Lemire
  • Patent number: 8969011
    Abstract: A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 3, 2015
    Assignee: 3M Innovative Properties Company
    Inventors: Manjiri T. Kshirsagar, Andrew W. Rabins
  • Patent number: 8956812
    Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: February 17, 2015
    Assignee: Bharat Biotech International Limited
    Inventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
  • Publication number: 20150037284
    Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicant: DSM IP ASSETS B.V.
    Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
  • Publication number: 20150037874
    Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
    Type: Application
    Filed: August 20, 2014
    Publication date: February 5, 2015
    Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
  • Publication number: 20150037873
    Abstract: The present invention relates to a method for endotoxin removal from a sample comprising the following steps: combining the sample comprising one or more target molecule(s) with a chromatography media comprising beads having an inner porous core functionalized with ligands capable of binding endotoxin and an outer porous layer without functional groups and a pore size small enough to exclude the target molecule from the inner core; and collecting the sample from the media, wherein the sample comprises an endotoxin level which is at least 75% less, preferably 90% less, than before the removal and the yield of the target molecule is at least 75%.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 5, 2015
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Patrik Adielsson, Tobias E. Soderman, Anna Akerblom
  • Patent number: 8945584
    Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: February 3, 2015
    Assignee: Hvidovre Hospital
    Inventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
  • Patent number: 8945904
    Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Heidi Trusheim, Peter Mason, Michael Franti, Bjoern Keiner, Melissa Sackal, Juerg Hunziker, Francois Natt, David Morrissey
  • Patent number: 8945581
    Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: February 3, 2015
    Assignee: Transgene S.A.
    Inventors: Daniel Malarme, Yves Cordier, Claude Sene
  • Publication number: 20150030565
    Abstract: The present invention provides a method to prepare purified enveloped (e.g., flavivirus) viral particle preparations employing ion exchange chromatography and tangential flow filtration.
    Type: Application
    Filed: January 8, 2013
    Publication date: January 29, 2015
    Applicant: Sanofi Pasteur Biologics, LLC
    Inventors: Sophia Mundle, Stephen Anderson
  • Patent number: 8940517
    Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: January 27, 2015
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Michael Graninger, Martin Kaliwoda
  • Publication number: 20150024467
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Application
    Filed: December 16, 2011
    Publication date: January 22, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Pauline McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Publication number: 20150017205
    Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.
    Type: Application
    Filed: July 15, 2014
    Publication date: January 15, 2015
    Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping
  • Patent number: 8932607
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • Patent number: 8932580
    Abstract: The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: January 13, 2015
    Assignees: Hyglos Invest GmbH, Biomerieux S.A.
    Inventors: Michael Schutz, Renate Grassl, Roman Meyer, Sibylle Frick, Ingrid Robl, Thomas Zander, Stefan Miller
  • Publication number: 20150010593
    Abstract: The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 8, 2015
    Inventors: Marciela Degrace, Nir Hacohen, Sagi Shapira, Liguo Wu
  • Publication number: 20150010983
    Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
  • Publication number: 20150004195
    Abstract: The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion ex change chromatography and tangential flow filtration.
    Type: Application
    Filed: January 9, 2013
    Publication date: January 1, 2015
    Inventors: Sophia Mundle, Stephen Anderson, Simon Delagrave